Position in APLS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,263,581
New position
Shares Held
56,266
first reported quarter
Ownership
0.044%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Capula Management Ltd holds $59,978,370 across 6 Biotechnology names. APLS ranks #4 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FOLD |
AMICUS THERAPEUTICS, INC.
|
3,191,610 | $46,150,680 | |
| 2 | TERN |
Terns Pharmaceuticals, Inc.
|
120,976 | $6,377,854 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
13,115 | $4,339,360 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
This page
|
56,266 | $2,263,581 | |
| 5 | MRNA |
Moderna, Inc.
|
14,500 | $736,600 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
247 | $110,295 |
All Filings in APLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,263,581 | 56,266 | Shares | Defined | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||